Finally, a drug discovery team from Abbott provides their take on why they like seldi versus older methods:
>>A novel method for the detection and quantitation of recombinant Kringle 5 in plasma using SELDI-MS
Lora A. Tucker-Garcia, Evelyn McKeegan, Scott E. Warder, Jieyi Wang, Don Davidson, Randy Bell, Cancer Research, Pharmaceutical Drug Discovery, Abbott Laboratories, Abbott Park, IL.
Kringle 5 (K5) of plasminogen is an anti-angiogenic protein with anti-tumor effects in vivo. The detection of recombinant K5 (rK5) in plasma is a challenge because it is a component of plasminogen, which is an abundant protein in plasma. Separation of rK5 from plasminogen is necessary for rigorous quantitation. A method using electrophoretic separation of rK5 and plasminogen on an SDS-PAGE gel followed by Western blot detection of rK5 was explored and provided useful data. However, the Western Blot based method is time and labor intensive and would not be feasible for the analysis of clinical samples. Here we show a novel method utilizing seldi technology to rapidly detect and quantify K5 in plasma. It is noteworthy that the samples are not subjected to any pre-fractionation and only 1 ìl of plasma is required. Currently, this method shows excellent linearity down to 0.5 ìg/ml K5 in plasma. Our previous observation of K5 in the urine of cancer patients, detected by Western blot analysis, has prompted us to apply our seldi approach to these samples. The analyses of urine and plasma samples from cancer patients will be presented.<<
Cheers, Tuck |
